New pill shows promise in early trial for Hard-to-Treat breast cancer

NCT ID NCT07408089

Terminated Disease control Sponsor: Boundless Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for side effects, with about 96 participants expected to join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

NEXT Oncology

Austin, Texas, 78758, United States
NEXT Oncology

Houston, Texas, 77054, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
The START Center for Cancer Care

San Antonio, Texas, 78229, United States
The START Center for Cancer Research

Los Angeles, California, 90025, United States
The START Center for Cancer Research

Lake Success, New York, 11042, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.